Addition to inhaled corticosteroids of leukotriene receptor antagonists versus theophylline for symptomatic asthma: a meta-analysis

Xin Chen1*, Ying-Bo Kang2*, Li-Qing Wang3*, Yun Li1, Yu-Wen Luo1, Zhe Zhu1, Rui Chen4

1Department of Respiratory Diseases, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, China; 2Department of Pharmacy, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China; 3Department of Pharmacy, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, China; 4Department of Respiratory Diseases, SUN Yat-sen Memorial Hospital, SUN Yat-sen University, Guangzhou 510120, China

*These three authors contributed equally to this article.

Background: Inhaled corticosteroids (ICSs) are widely used in combination with second controller medications in the management of asthma in adults and children. There lacks a systematic comparison between addition of leukotriene receptor antagonists (LTRAs) and theophylline to ICS. The purpose of this meta-analysis was to evaluate the difference of the efficacy and safety profile of adding either LTRAs or theophylline to ICS in adults and children with symptomatic asthma.

Methods: Randomised controlled trials (RCTs) published prior to November 2014 were acquired through systematically searching and selected based on the established inclusion criteria for publications. The data extracted from the included studies were further analyzed by a meta-analysis.

Results: We included eight RCTs, of which six recruited adults and two recruited children aged 5 to 14 years. The primary outcomes were changes in lung function from baseline, including forced expiratory volume in the first second (FEV1) and peak expiratory flow (PEF). Overall, addition of LTRAs led to significantly better morning PEF [mean difference (MD) 16.94 [95% confidence interval (CI): 11.49-22.39] L/min, P<0.01] and FEV1 [MD 0.09 (95% CI: 0.03-0.15) L, P=0.005] as compared to addition of theophylline. There were no differences between the two treatments in terms of evening PEF, adverse events, rescue medication use and asthma exacerbation.

Conclusions: The combination of LTRA and ICS leads to modestly greater improvement in lung function than the combination of theophylline and ICS in the treatment of symptomatic asthma. Long-term trials are required to assess the efficacy and safety of these two therapies.

Keywords: Inhaled corticosteroids (ICSs); leukotriene receptor antagonists (LTRAs); theophylline; meta-analysis

Submitted Dec 07, 2014. Accepted for publication Feb 28, 2015.
View this article at: http://dx.doi.org/10.3978/j.issn.2072-1439.2015.04.12

Introduction

Asthma is a common chronic inflammatory disorder of the airways characterized by variable and recurring symptoms, reversible airflow obstruction and bronchial spasm (1). Anti-inflammatory therapy is the pharmacologic mainstay of asthma treatment and inhaled corticosteroids (ICSs) are currently the most effective anti-inflammatory medications in reducing asthma symptoms, improving the lung function, and reducing the airway inflammation in asthma.

When the asthma is poorly controlled by ICS monotherapy, other drugs such as long acting β2 agonists (LABAs), leukotriene receptor antagonists (LTRAs) and sustained release theophylline can be added. The recommended option is to combine a low dose of ICS with LABA (2). Addition of LABA leads to greater improvement in lung function, symptoms, and use of rescue β2 agonists,
and to reduce the risk of exacerbations than increasing the dose of ICS (3). In addition, the approach of using a single inhaler containing ICS and LABA for both maintenance and reliever therapy (SMART) is reported to be superior in preventing exacerbations compared with conventional ICS-LABA combination (4). However, the safety of LABA has been challenged in recent years, especially when used without concomitant ICS (5). Although there is no conclusive evidence that addition of LABA could increase the risk of asthma-related hospitalizations or asthma mortality, the concern about its performance of enhancing airway remodeling still exists (6-9). Another meta-analysis also reported an increase in the risk of serious adverse events associated with LABA (10).

Both LTRAs and theophylline have anti-inflammatory effects (11,12). There is some evidence to support the synergistic effect of these two add-on therapies at the cellular or pathophysiology level. LTRAs inhibit the production of cysteinyl leukotrienes, important pro-inflammatory mediators in asthma that are unaffected by steroid treatment (12-14). Theophylline may reduce mucosal permeability and attenuate development of asthma inflammation after allergen challenge (15). Many clinical trials have also shown the addition of LTRA or theophylline to be effective in asthma treatment (16-18). Thus, both addition of LTRAs or theophylline may potentiate the anti-inflammatory effect of ICS and lead to better asthma control. A number of trials aimed to compare these two add-on therapies have been carried out over the last decade, but these studies had very small sample of patients in both groups. Therefore, we evaluated the relative benefits and safety profile of adding either LTRAs or theophylline to ICS in patients with symptomatic asthma in a systematic manner.

Methods

Data sources

We searched PubMed, Excerpta Medica Database (EMBASE), ScienceDirect, ClinicalTrials.gov, Chinese Biomedical Database and the Cochrane Central Register of Controlled Trials (CENTRAL) for potentially relevant articles published until Nov 2014, with no lower date limit applied. The following search strategy was used: “leukotriene receptor antagonist OR montelukast OR pranlukast OR zafirlukast” and “theophylline” and “steroid OR ICSs OR budesonide OR beclomethasone OR fluticasone” and “asthma”. These searches were supplemented by hand searching of leading respiratory journals and conference abstracts. Reference lists were searched for additional articles.

Study selection

Two reviewers (X Chen and YB Kang) screened the title, abstract or citations and excluded all studies that clearly did not fit the inclusion criteria. Studies included in the meta-analysis met the following criteria: (I) studies should be RCTs conducted in asthmatic adults or children in whom LTRAs or theophylline were added, as a fixed dose combination, to ICS; (II) despite being treated with ICS, patients had asthmatic symptoms prior to study entry or during the run-in period; (III) the intervention must have been administered for a minimum of 4 weeks. Both blinded and non-blinded trials were included.

Data extraction and quality assessment

Data for the trials were extracted by two reviewers independently. If disagreement arose, all the authors conferred till a consensus was arrived at. The extracted data included the characteristics, study design and outcomes from papers. The primary outcomes were changes in lung function from baseline, including forced expiratory volume in the first second (FEV₁) and peak expiratory flow (PEF). The secondary outcomes were the number of adverse events reported, the use of rescue medication and asthma exacerbations.

The RCTs included in our meta-analysis were assessed for methodological quality by using the 5-point scale (0= worst and 5= best) described by Jadad et al. (19). The maximum score that could be awarded to a trial was five points and a score higher than 2 was considered to be indicative of adequate methodological quality (20).

Statistical analysis

This meta-analysis was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (21). All included trials were combined using Review Manager 5.2 (The Cochrane Collaboration, Software Update, Oxford, UK). For dichotomous variables, we combined data as risk ratio (RR) with 95% confidence interval (CI). For continuous outcomes, such as pulmonary function tests, we combined
data as mean difference (MD) with 95% CI. Chi-square-based Q-statistic test and I² test were applied to assess the homogeneity of effect sizes between studies. I² > 50% or P < 0.10 represent the cut-off level for statistical significance respectively. In the absence of heterogeneity, we used a fixed-effect model. If heterogeneity was suggested, a random-effects model was chosen. Sensitivity analysis was conducted on a statistical method of analysis (random vs. fixed effects model).

Results

Study selection and methodological quality

The flowchart shows the detailed selection process according to PRISMA guideline (Figure 1). Initially, 149 articles were identified from the literature searches and we excluded 137 that were either not relevant or had duplicate data. Twelve full-text articles were reviewed for detail evaluation. Of these, four trials were further excluded according to the inclusion criteria (22-25). Finally, eight RCTs fulfilled the inclusion criteria and were selected for meta-analysis (26-33). Using the methods of Jadad et al., five studies were found to have a Jadad score of 3-5 and three studies were found to have a Jadad score of 2. We established a database according to the extracted information from each study.

Study characteristics

The inclusion criteria and study characteristics are given in Tables 1 and 2. Six studies focused on adults and two on children exclusively. A total of 160 children and 300 adults were recruited in the studies. The patients in all of the studies showed symptoms before randomized to treatment.

Primary outcomes

Changes from baseline in morning PEF

Six trials examined mean morning PEF and five studies contributed data to this analysis (330 participants including 75 children and 255 adults). Addition of LTRA resulted in a significantly greater improvement in morning PEF than addition of theophylline [MD 16.94 (95% CI: 11.49-22.39) L/min, P<0.00001, I²=28%] (Figure 2).

Changes from baseline in evening PEF

Four studies were considered for this analysis (270 participants including 75 children and 195 adults). There was no significant difference between these two therapies in improving evening PEF in asthmatics [MD 6.01 (95% CI: -2.85 to 14.87) L/min, P=0.18, I²=24%] (Figure 3).

Changes from baseline in FEV₁ (L)

Two studies contributed data to changes in FEV₁ (including 108 adults). ICS plus LTRA was superior to ICS plus theophylline therapy in improving FEV₁ in asthmatics [MD 0.09 (95% CI: 0.03-0.15) L, P=0.005, I²=0%] (Figure 4).

Sensitivity analysis

To evaluate the sensitivity of meta-analysis, we calculated...
the random effect model for morning PEF. The random effect model of morning PEF showed a pooled MD of 14.92 (95% CI: 6.73-23.10), similar to the result [MD 16.94 (95% CI: 11.49-22.39)] obtained from the fixed-effect model (Figure 5).

Secondary outcomes

Adverse events

Five studies with 297 participants (including 168 children and 129 adults) reported adverse events, and their results showed that there were no statistical differences in adverse

Table 2 Characteristics and study design of trials included

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study design</th>
<th>Patients (n)</th>
<th>Men (%)</th>
<th>Dropouts (%)</th>
<th>Duration (weeks)</th>
<th>ICS dosage (µg/day)</th>
<th>LTRA dosage (mg/day)</th>
<th>Theo (mg/day)</th>
<th>Theo plasma level (µg/mL)</th>
<th>Quality score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dempsey et al. (26)</td>
<td>RCT (SB)</td>
<td>24</td>
<td>33.3</td>
<td>14.3</td>
<td>4</td>
<td>BDP/800</td>
<td>ZAF/40</td>
<td>400</td>
<td>6.7</td>
<td>3</td>
</tr>
<tr>
<td>Yurdakul et al. (27)</td>
<td>RCT</td>
<td>39</td>
<td>33.3</td>
<td>Unclear</td>
<td>12</td>
<td>BUD/800</td>
<td>ZAF/40</td>
<td>400</td>
<td>Unclear</td>
<td>2</td>
</tr>
<tr>
<td>Tsuchida et al. (28)</td>
<td>RCT (SB)</td>
<td>67</td>
<td>47.8</td>
<td>Unclear</td>
<td>4</td>
<td>BDP/800</td>
<td>PRA/500</td>
<td>200</td>
<td>5.4±0.7</td>
<td>2</td>
</tr>
<tr>
<td>Shah et al. (29)</td>
<td>RCT (DB)</td>
<td>60</td>
<td>81.7</td>
<td>5.0</td>
<td>8</td>
<td>BUD/400</td>
<td>MON/10</td>
<td>400</td>
<td>6.2</td>
<td>5</td>
</tr>
<tr>
<td>kondo et al. (30)</td>
<td>RCT</td>
<td>75</td>
<td>58.7</td>
<td>6.0</td>
<td>4</td>
<td>BDP/100-400</td>
<td>MON/5</td>
<td>200-400</td>
<td>4.8</td>
<td>3</td>
</tr>
<tr>
<td>Li et al. (31)</td>
<td>RCT</td>
<td>80</td>
<td>56.3</td>
<td>Unclear</td>
<td>6</td>
<td>BUD/800</td>
<td>MON/10</td>
<td>400</td>
<td>Unclear</td>
<td>2</td>
</tr>
<tr>
<td>Yang et al. (32)</td>
<td>RCT</td>
<td>85</td>
<td>57.6</td>
<td>3.4</td>
<td>12</td>
<td>BUD/200</td>
<td>MON/10</td>
<td>200</td>
<td>Unclear</td>
<td>3</td>
</tr>
<tr>
<td>Patel et al. (33)</td>
<td>RCT</td>
<td>30</td>
<td>50.0</td>
<td>10.0</td>
<td>8</td>
<td>BUD/400</td>
<td>MON/10</td>
<td>400</td>
<td>Unclear</td>
<td>3</td>
</tr>
</tbody>
</table>

RCT, randomised controlled trials; DB, double blind; SB, single blind; BDP, beclometasone dipropionate; BUD, budesonide; ZAF, zafirlukast; PRA, pranlukast; MON, montelukast; Theo, theophylline.
### Table 1: Comparison of ICS+LTRA versus ICS+Theophylline

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>ICS+LTRA</th>
<th>ICS+Theophylline</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dempsey 2002</td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
</tr>
<tr>
<td></td>
<td>22</td>
<td>62.6</td>
<td>24</td>
<td>64.3</td>
</tr>
<tr>
<td>Kondo 2006</td>
<td>31</td>
<td>33.4</td>
<td>39</td>
<td>36.2</td>
</tr>
<tr>
<td>Li 2012</td>
<td>42</td>
<td>62.6</td>
<td>40</td>
<td>65.8</td>
</tr>
<tr>
<td>Shah 2006</td>
<td>33</td>
<td>12.6</td>
<td>30</td>
<td>13.3</td>
</tr>
<tr>
<td>Tsuchida 2003</td>
<td>13.6</td>
<td>33.6</td>
<td>33</td>
<td>32.6</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>166</td>
<td></td>
<td>164</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi²=5.53, df=4 (P=0.24), I²=28%
Test for overall effect: Z=6.09 (P<0.00001)

**Figure 2** Effects of ICS + LTRA versus ICS + theophylline on morning PEF (L/min). ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; PEF, peak expiratory flow.

### Table 2: Comparison of ICS+LTRA versus ICS+Theophylline

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>ICS+LTRA</th>
<th>ICS+Theophylline</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dempsey 2002</td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
</tr>
<tr>
<td></td>
<td>18</td>
<td>64.8</td>
<td>24</td>
<td>67</td>
</tr>
<tr>
<td>Kondo 2006</td>
<td>24.7</td>
<td>29.1</td>
<td>39</td>
<td>29.7</td>
</tr>
<tr>
<td>Li 2012</td>
<td>47</td>
<td>67.1</td>
<td>40</td>
<td>64.2</td>
</tr>
<tr>
<td>Tsuchida 2003</td>
<td>10</td>
<td>30.6</td>
<td>33</td>
<td>27.3</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>136</td>
<td></td>
<td>134</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi²=3.96, df=4 (P=0.27), I²=24%
Test for overall effect: Z=1.33 (P=0.18)

**Figure 3** Effects of ICS + LTRA versus ICS + theophylline on evening PEF (L/min). ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; PEF, peak expiratory flow.

### Table 3: Comparison of ICS+LTRA versus ICS+Theophylline

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>ICS+LTRA</th>
<th>ICS+Theophylline</th>
<th>Mean Difference</th>
<th>Mean Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dempsey 2002</td>
<td>Mean</td>
<td>SD</td>
<td>Total</td>
<td>Mean</td>
</tr>
<tr>
<td></td>
<td>0.23</td>
<td>0.64</td>
<td>24</td>
<td>0.63</td>
</tr>
<tr>
<td>Shah 2006</td>
<td>0.30</td>
<td>0.12</td>
<td>30</td>
<td>0.21</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>54</td>
<td></td>
<td>54</td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi²=0.05, df=4 (P=0.83), I²=0%
Test for overall effect: Z=2.79 (P=0.005)

**Figure 4** Effects of ICS + LTRA versus ICS + theophylline on FEV₁ (L). ICS, inhaled corticosteroid; LTRA, leukotriene receptor antagonist; FEV₁, forced expiratory volume in the first second.

Events between the groups [RR 1.31 (95% CI: 0.77-2.24), P=0.32, I²=0%] (Figure 6).

**Decrease in rescue medication use (puffs/day)**

Four studies were considered for this analysis (212 participants including 46 children and 166 adults). There was no significant difference between these two therapies in the use of rescue medication [MD -0.01 (95% CI: -0.21 to 0.19), P=0.70, I²=0%].
**Asthma exacerbations**

Two studies in 143 participants (including 83 children and 60 adults) contributed data for this outcome. There was no significant difference between the two treatments [RR 1.00 (95% CI: 0.31-3.20), P=0.99, I²=0%].

**Discussion**

Currently, LTRAs are generally considered to be of more importance than theophylline in the therapies for asthma. LTRA monotherapy is recommended as the alternative option at step 2 according to Global Initiative for Asthma (GINA) while theophylline has become a third-line treatment in many industrialized countries (2). Even so, theophylline is still widely used in China, especially in its less developed areas. The Chinese clinicians prefer to adopt the regimen lower than routine dose and many of them value its additional effects (34,35). A meta-analysis combined four RCTs including 182 asthmatic patients reported that ICS plus LTRA results in greater improvement in pulmonary function test parameters than ICS plus theophylline (25). However, more trials comparing these two therapies have been conducted since the previous review was carried out, which include studies conducted in children and Chinese people. In the light of these new evidences, it is necessary to reassess the efficacy and safety of ICS-LTRA as compared to ICS-theophylline.

The results of our meta-analysis indicate that addition of LTRA results in more improvement in both morning PEFL/min (MD 16.94 L/min, 95% CI: 11.49-22.39) and FEV₁ (MD 0.09 L, 95% CI: 0.03-0.15) as compared to addition of theophylline in patients who remain symptomatic with the prescription of low to moderate doses of ICS. There was no statistical heterogeneity, and the sensitivity analysis showed that the random and fixed effect models for morning PEFL/min had similar results.
for meta-analysis. However, data on other clinically relevant outcomes that could be pooled were sparse. In fact, the included individual studies failed to prove any superiority of LTRA than theophylline with regard to asthma related symptoms, quality of life and exacerbations. Further investigations aimed at the effects of ICS-LTRA versus ICS-theophylline on clinically relevant outcomes are required.

No significant statistical difference was found in adverse events between the two therapies. A major limitation of theophylline is the high frequency of adverse effects, such as headache, nausea, abdominal discomfort and cardiac arrhythmias (36). However, few adverse events were observed in the theophylline groups of included studies. This could be interpreted as a result of the low doses of theophylline that give plasma concentrations of 5 to 10 μg/mL, coinciding with the anti-inflammatory target range but having less adverse reaction. The results of meta-analysis showed that there were no statistical differences in need for rescue medication between the two treatments during the study period. This was also supported by the study conducted by Yurdakul et al. (27), which had a relatively long follow-up period by 3 months among the included studies. Two of the included trials reported asthma exacerbation rates and the results showed that there were no statistical differences between the groups. The conclusion of our meta-analysis is similar to the study conducted by Fang et al. (25) and we found that it may be applied to children.

Leucotriene receptor antagonists are a relatively new class of antiasthmatic drugs while theophylline is an old drug that has been used for over 70 years. Both LTRAs and theophylline have the advantage of being administered orally. Many studies indicated that adding LTRAs to ICS significantly improved lung function and asthmatic symptoms in comparison with increasing the dose of ICS (37-39). LTRAs could also increase patient compliance and bring remarkable ease of anti-inflammatory treatment administration (40). Furthermore, LTRAs are well tolerated, and few if any class-related effects have so far been recognized (2). The results of our study indicate that LTRAs show greater beneficial effects in increasing PEF and FEV₁ compared with theophylline. LTRAs could be a good choice as add-on therapy for asthmatic patients treated with low to moderate ICS. However, oral sustained release theophylline may also be an attractive steroid-sparing agent considering its lower costs and efficacy, especially in developing countries (41). The adverse effects of theophylline generally occur over the serum concentration range of 15 to 20 μg/mL and can be significantly decreased by given at low doses. It’s worth mentioning that in such patients the withdrawal of sustained release theophylline has been associated with deterioration of control (42).

There were several limitations in this meta-analysis. First, some of the studies did not present data suitable for meta-analysis so that we could not investigate whether or not agents (different LTRAs or different ICSs), or duration of treatment affect the evaluation of these two therapies. For the same reason, the subgroup analyses on children versus adults could not be examined. So the results of this study are more suitable for adults. Second, the funnel plot was not created for evaluation of the publication bias owning to the limited studies available for meta-analysis. So there exists a possibility of publication bias in this meta-analysis. Despite these limitations, we believe that these pooled results provide helpful information.

Conclusions

Our meta-analysis suggests that the combination of LTRA and ICS leads to modestly greater improvement in lung function than the combination of theophylline and ICS. But no statistically significant differences are found in rescue medication use, adverse effects and asthma exacerbation between the two therapies. More randomized controlled trials in the form of large sample and long duration are required due to our study limitations.

Acknowledgements

Funding: This study was funded by the Guangdong Provincial Science and Technology Project (2011B080701062), (2013B022000072) and Guangdong Natural Science Foundation (S2012101008623).

Authors’ contributions: Conceived and designed the experiments: R Chen, LQ Wang. Selected studies and extracted data: X Chen, YB Kang, Y Li. Analyzed the data: X Chen, YB Kang, Y Li, YW Luo, Z Zhu. Wrote the paper: YB Kang, X Chen, R Chen.

Disclosure: The authors declare no conflict of interest.

References

3. Ducharme FM, Ni Chroinin M, Greenstone I, et


28. Tsuchida T, Matsuse H, Machida I, et al. Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids.